Kashiha Arefeh, Setayesh Neda, Panahi Yunes, Ahmadi Arezoo, Soltany-Rezaee-Rad Mohammad, Najafi Atabak, Rouini Mohammad Reza, Namipashaki Atefeh, Sahebkar Amirhossein, Mojtahedzadeh Mojtaba
Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Department of Pharmaceutical Biotechnology and Pharmaceutical Biotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Acta Biomed. 2018 Jun 7;89(2):193-202. doi: 10.23750/abm.v89i2.5385.
Invasive candidiasis management through the rapid initiation of appropriate antifungal therapy has been shown to be associated with the better prognosis, improved clinical outcome and reduced mortality in critically ill patients. Therefore, selection of an appropriate antifungal therapy should be based on the distribution of candida species and the pattern of antifungal resistance. This study aimed to assess the prevalence of candidemia and associated subtypes following severe sepsis in non-neutropenic critically ill patients.
This study was a cross-sectional study that was conducted on severe sepsis patients stayed at least seven days in intensive care unit. Patients less than 18 years old, pregnant and breastfeeding patients, immunocompromised patients, neutropenic patients, patients with concurrent use of antifungal medicines and cytotoxic agents were excluded.To asses the candidemia, one mililiter of patients' blood sample was collected. Sample analysis was performed by Real-Time PCR and high resolution melting curve analysis method.
Thirty-one critically ill patients were recruited in this study over 12-month period. Candidemia with a detection limit of 100 pg per 0.2 ml blood sample was not recognized in any of the included patients.
The present result indicates low incidence of candidemia in the targeted intensive care units, but other factors such as small sample size, exclusion of patients with compromised immune system and the low fungal load at the time of sampling may also account for our observation.
通过迅速启动适当的抗真菌治疗来管理侵袭性念珠菌病,已被证明与危重症患者的预后改善、临床结局改善及死亡率降低相关。因此,选择适当的抗真菌治疗应基于念珠菌属的分布及抗真菌耐药模式。本研究旨在评估非中性粒细胞减少的危重症患者严重脓毒症后念珠菌血症的患病率及相关亚型。
本研究为横断面研究,对象为在重症监护病房至少住院7天的严重脓毒症患者。排除年龄小于18岁的患者、孕妇及哺乳期患者、免疫功能低下患者、中性粒细胞减少患者、同时使用抗真菌药物和细胞毒性药物的患者。为评估念珠菌血症,采集患者1毫升血样。采用实时荧光定量聚合酶链反应和高分辨率熔解曲线分析方法进行样本分析。
在12个月期间,本研究招募了31例危重症患者。在所纳入的患者中,未检测到每0.2毫升血样中念珠菌血症检测限为100皮克的情况。
目前的结果表明,目标重症监护病房中念珠菌血症的发生率较低,但其他因素,如样本量小、排除免疫系统受损患者以及采样时真菌载量低,也可能解释我们的观察结果。